Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.75% -0.23% 51.64M 8355.83
Weighted Average Dividend Yield Turnover Ratio (Generic) 1 Year Fund Level Flows Max Drawdown (Since Inception)
1.13% 85.00% -31.20M Upgrade

Basic Info

Investment Strategy
The Fund seeks to provide long-term growth of capital by investing at least 80% of its net assets, in companies that derive at least 50% of revenues from products or services related to GLP-1 and treatment of cardiovascular diseases and/or metabolic diseases defined by Centers for Diseases Control and Preventions.
General
Security Type Exchange-Traded Fund
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Tema
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Performance Versus Peer Group

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Peer Group Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Peer Group (NAV)
--
--
--
--
--
--
--
--

Annual Total Returns Versus Peers

Loading chart...
Name
2018
2019
2020
2021
2022
2023
2024
YTD
--
--
--
--
--
--
-4.30%
19.99%
-8.71%
27.67%
15.90%
21.82%
-18.14%
23.79%
18.67%
20.21%
-1.47%
25.24%
18.96%
3.91%
-8.62%
9.64%
7.04%
18.27%
--
--
--
--
--
-5.41%
-4.66%
25.41%
--
--
--
--
--
--
-1.01%
12.36%
--
--
--
--
--
--
--
--
As of December 10, 2025.

Asset Allocation

As of November 30, 2025.
Type % Net
Cash 0.36%
Stock 99.26%
Bond 0.31%
Convertible 0.00%
Preferred 0.00%
Other 0.07%
View Asset Allocation
Start Trial

Basic Info

Investment Strategy
The Fund seeks to provide long-term growth of capital by investing at least 80% of its net assets, in companies that derive at least 50% of revenues from products or services related to GLP-1 and treatment of cardiovascular diseases and/or metabolic diseases defined by Centers for Diseases Control and Preventions.
General
Security Type Exchange-Traded Fund
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Tema
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Top Portfolio Holders